Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHAMELEON: SC vs IV Infliximab Switching in Crohn's Disease
NCT06064864Recruiting
- Sponsor
- Asan Medical Center
- Start
- Oct 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of infliximab in Crohn's disease (3 arms), sponsored by Asan Medical Center. Primary endpoint: Deep remission rate at Week 54. Started Oct 2023; status: recruiting.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06064864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06064864.